Prognostic role of selective beta-1 blockers in patients treated with immune checkpoint inhibitors
Supportive Care in Cancer · 2026-11 · 34 (11)
DOI: 10.1007/s00520-026-11366-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 26.10.2026. Verfasst von Moran Gvili Perelman und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Tel-Aviv Sourasky University Medical Center, 6 Weizmann Street, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Adrenergic beta-1 Receptor Antagonists, Cardiovascular Diseases. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Purpose
Immune checkpoint inhibitors (ICIs) have revolutionized cancer care and prognosis. Beta-adrenergic activation contributes to cancer initiation and progression. While non-selective beta-blockers were found to improve the efficacy of ICIs therapy, the role of beta-1 (β1)-selective beta-blocker (β_1B) is unknown. We aimed to evaluate the association between baseline selective β1-blocker therapy and all-cause mortality and cardiovascular immune-related adverse events (CV irAEs) among patients treated with ICIs.
Methods
We performed a retrospective single-center study including patients diagnosed with cancer and treated with ICIs therapy.
Results
Among 2409 patients, 591 (25%) were pretreated with β_1B. Patients in the β_1B group were older (72 ± 9 vs. 64 ± 13 years, p < 0.001) with a higher prevalence of cardiac risk factors and CV diseases including ischemic heart disease (40% vs. 8%, p < 0.001), heart failure (HF) (9% vs. 2%, p < 0.001) and atrial fibrillation (AF) (15% vs. 3%, p < 0.001). Patients pretreated with β_1B showed significantly increased all-cause mortality (68% vs. 57%, p < 0.001) and CV irAEs (14% vs. 7%, p < 0.001), mainly HF (7% vs. 3%, p < 0.001) and AF (7% vs. 3%, p < 0.001). In a multivariate analysis, β_1B remained a strong independent predictor for all-cause mortality (Hazard Ratio (HR) 1.21 [95% CI 1.05–1.39]), p = 0.010), however, not for CV irAEs (HR 1.22 [95% CI = 0.84–1.77], p = 0.290). The association between baseline selective β1-blocker treatment and increased all-cause mortality was consistent among patients with or without baseline CV disease.
Conclusions
Baseline β_1B therapy may be an independent predictor of increased all-cause mortality in patients treated with ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Tel-Aviv Sourasky University Medical Center, 6 Weizmann Street, Tel Aviv, Israel.
- Gray Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Division of Oncology, Tel-Aviv Sourasky University Medical Center, Tel Aviv, Israel.
- Internal Medicine T, Tel-Aviv Sourasky University Medical Center, Tel Aviv, Israel.
- Internal Medicine T, Chaim Sheba Medical Center, Ramat-Gan, Israel.
- Division of Cardiology, Tel-Aviv Sourasky University Medical Center, 6 Weizmann Street, Tel Aviv, Israel. michallp@tlvmc.gov.il.
Zitieren
APA
Perelman, M. G., Brzezinski, R. Y., Gefen, S., Merin, R., Miodovnik, M., Raphael, A., Wolf, I., Hemed, A. R., Perelman, M., Slieman, M., Khoury, S., Havakuk, O., Topilsky, Y., Banai, S., Leshem, Y., & Laufer-Perl, M. (2026). Prognostic role of selective beta-1 blockers in patients treated with immune checkpoint inhibitors. Supportive Care in Cancer, 34(11). https://doi.org/10.1007/s00520-026-11366-7
Vancouver
Perelman MG, Brzezinski RY, Gefen S, Merin R, Miodovnik M, Raphael A, et al. Prognostic role of selective beta-1 blockers in patients treated with immune checkpoint inhibitors. Supportive Care in Cancer. 2026;34(11). doi:10.1007/s00520-026-11366-7
BibTeX
@article{Perelman2026,
author = {Perelman, Moran Gvili and Brzezinski, Rafael Y and Gefen, Sheizaf and Merin, Roei and Miodovnik, Mor and Raphael, Ari and Wolf, Ido and Hemed, Anna Rozenfeld and Perelman, Maxim and Slieman, Moaad and Khoury, Shafik and Havakuk, Ofer and Topilsky, Yan and Banai, Shmuel and Leshem, Yasmin and Laufer-Perl, Michal},
title = {Prognostic role of selective beta-1 blockers in patients treated with immune checkpoint inhibitors},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {11},
doi = {10.1007/s00520-026-11366-7}
}
EUVIMED